Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis
- 5 March 2020
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (5) , 1902150
Abstract
Background: High exhaled nitric oxide fraction (FENO) levels are associated with greater risk of asthma exacerbation. However, it is not clear howFENOcan be used to guide safe reductions in inhaled corticosteroid (ICS) doses in asthma patients. This study assesses the ability ofFENOto guide ICS reductions.Methods: Systematic searching of electronic databases identified prospective observational studies and randomised controlled trials which recruited participants with mild-to-moderate asthma aged ≥12 years and measuredFENObefore reducing ICS. We performed multilevel mixed-effects logistic regression in relation to acute exacerbations and estimated each participant's exacerbation risk using our logistic regression model.Results: We included data from seven out of eight eligible studies, representing 384 participants. ICS doses were halved in four studies and withdrawn in three studies. A baselineFENOmeasurement of ≥50 ppb was associated with increased risk of exacerbations (crude OR 3.14, 95% CI 1.41–7.00, p=0.005; adjusted OR 3.08, 95% CI 1.36–6.98, p=0.007) and corresponded to an estimated exacerbation risk cut-off of 15%. Reducing ICS when estimated exacerbation risk was versusversus141 (36.7%) out of 384), but similar proportions of patients avoiding exacerbations (222 (91.4%) out of 243, 95% CI 87.1–94.6%versus311 (90.4%) out of 344, 95% CI 86.8–93.3%).Conclusion: In patients with mild-to-moderate asthma, gradual ICS reduction whenFENOis <50 ppb may help decrease ICS use without increasing exacerbations. Future research should aim to validate these findings in larger populations.Keywords
Funding Information
- Research Trainees Coordinating Centre (PDF-2016-09-007)
This publication has 42 references indexed in Scilit:
- The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trialsJournal of Allergy and Clinical Immunology, 2013
- Daily exhaled nitric oxide measurements and asthma exacerbations in childrenAllergy, 2011
- Viruses and bacteria in acute asthma exacerbations – A GA2LEN‐DARE* systematic reviewAllergy, 2010
- Down-titration from high-dose combination therapy in asthma: Removal of long-acting β2-agonistRespiratory Medicine, 2010
- Exhaled nitric oxide as a predictor of exacerbation in children with moderate-to-severe asthma: a prospective, 5-month studyAnnals of Allergy, Asthma & Immunology, 2009
- Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysisAnnals of Allergy, Asthma & Immunology, 2007
- The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trialJournal of Allergy and Clinical Immunology, 2007
- Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remissionThorax, 2005
- Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysisCommentary: Dosage needs systematic and critical reviewBMJ, 2001
- A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroidClinical & Experimental Allergy, 1992